Aarti Drugs Q1 Consolidated Revenue Tops ₹7.03 Billion

MUMBAI, India — Active Pharmaceutical Ingredients (API) and specialty chemicals manufacturer Aarti Drugs Limited reported a consolidated revenue from operations of ₹7.03 billion (₹70,278 lakhs) for the first quarter ended June 30, 2026. The company posted a consolidated net profit of ₹501.3 lakhs (₹50.13 crore) during the quarter, supported by sustained volume demand across its core pharmaceutical business segments.

The financial results, approved by the Board of Directors at its meeting on July 31, 2026, show a 19.1% top-line increase compared to ₹5,905.1 lakhs (₹590.51 crore) reported in the corresponding period of the previous fiscal year.

Detailed Performance Breakdown of Q1 FY27 Financial Results

The company's quarterly results filed with stock exchanges reflect stable growth across key operational metrics alongside ongoing margin pressures in the specialty generics segment.

Consolidated Income & Profitability Comparison

Expense Breakdown and Cost Structure

• Material Costs: Cost of materials consumed reached ₹46,935 lakhs, up from ₹42,719 lakhs in Q1 FY26.

• Employee Expenses: Employee benefits expenses totaled ₹3,651 lakhs compared to ₹3,228 lakhs in the prior-year quarter.

• Finance Costs: Finance costs were recorded at ₹922 lakhs, compared to ₹816 lakhs in the preceding quarter.

• Depreciation: Depreciation and amortization expenses stood at ₹1,846 lakhs.

• Exceptional Item Note: Exceptional item of ₹2.09 crore (₹209 lakhs) represents a write-off of Capital Work-in-Progress (CWIP) for an administrative building as part of routine expansion plans.

Standalone Performance Highlights

On a standalone basis, Aarti Drugs Limited generated revenue from operations of ₹62,745 lakhs (₹627.45 crore) for the quarter ended June 30, 2026, up 20.4% from ₹52,096 lakhs in Q1 FY26. Standalone profit before tax stood at ₹6,785 lakhs, while standalone net profit after tax reached ₹5,085 lakhs (₹50.85 crore). Standalone Basic EPS for the quarter was ₹5.57.

Official Sources Section

According to official regulatory disclosures submitted under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

• The financial statements were audited by statutory auditors Gokhale & Sathe, Chartered Accountants, who issued an unmodified audit opinion.

• The results were reviewed by the Audit Committee and subsequently approved by the Board of Directors in Mumbai on July 31, 2026.

• Official filings were uploaded to the corporate portals of the
  National Stock Exchange of India
  and
  BSE Limited

Quote Section

According to official filings signed by Chairman, Managing Director & CEO Prakash M. Patil:

"The audited standalone and consolidated financial results for the quarter ended June 30, 2026, have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013."

Why It Matters

Aarti Drugs' solid top-line performance reflects healthy underlying demand for bulk active pharmaceutical ingredients in domestic and global healthcare markets. For investors and pharma sector analysts, monitoring the company's input costs, expansion projects, and margin stability remains critical as API manufacturers navigate raw material price volatility and regulatory compliances.

Key Facts at a Glance

• Consolidated Revenue: ₹7.03 billion (₹70,278 lakhs) in Q1 FY27, up 19.1% YoY.

• Consolidated Net Profit: ₹50.13 crore (₹5,013 lakhs) for the quarter.

• Exceptional Item: Write-off of ₹2.09 crore CWIP related to building expansion.

• Earnings Per Share: Consolidated basic EPS recorded at ₹5.49.

Frequently Asked Questions (FAQ)

What was Aarti Drugs' revenue for Q1 FY27?

Aarti Drugs reported consolidated revenue from operations of ₹7.03 billion (₹70,278 lakhs) for the quarter ended June 30, 2026.

What was the consolidated net profit of Aarti Drugs in Q1 FY27?

The company reported a consolidated net profit after tax of ₹50.13 crore (₹5,013 lakhs) during the first quarter.

What caused the exceptional item in Aarti Drugs' Q1 FY27 results?

The exceptional item of ₹2.09 crore represents the write-off of Capital Work-in-Progress (CWIP) pertaining to an administrative building as part of routine expansion adjustments.

Source: BSE Limited, National Stock Exchange of India, Ministry of Health and Family Welfare.